Abbonarsi

Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial - 17/09/20

Doi : 10.1016/j.ahj.2020.08.001 
Oliver K. Jawitz, MD, MHS a, b, , Morgan L. Cox, MD, MHS a, b, David Ranney, MD a, Judson B. Williams, MD, MHS a, c, Hillary Mulder, MS b, Mario F.L. Gaudino, MD d, Stephen Fremes, MD e, Robert H. Habib, PhD f, C. Michael Gibson, MD, MS g, Thomas A. Schwann, MD h, Renato D. Lopes, MD, PhD b, John H. Alexander, MD, MHS b
a Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA 
b Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA 
c WakeMed Clinical Research Institute, Raleigh, NC, USA 
d Weill Cornell Medical Center, New York, NY, USA 
e Department of Surgery, University of Toronto, Toronto, Ontario, Canada 
f The Society of Thoracic Surgeons Research Center, Chicago, IL, USA 
g Beth Israel Deaconess Medical Center, Cardiovascular Division, Boston, MA, USA 
h University of Massachusetts-Baystate, Springfield, MA, USA 

Reprint requests: Oliver K. Jawitz, MD, MHS, Department of Surgery, Duke University School of Medicine, Duke Clinical Research Institute, 200 Morris St, Durham, NC 27701.Department of SurgeryDuke University School of Medicine, Duke Clinical Research Institute200 Morris StDurhamNC27701

Abstract

Background

The optimal role of radial artery grafts in coronary artery bypass grafting (CABG) remains uncertain. The purpose of this study was to examine angiographic and clinical outcomes following CABG among patients who received a radial artery graft.

Methods

Patients in the angiographic cohort of the PREVENT-IV trial were stratified based upon having received a radial artery graft or not during CABG. Baseline characteristics and 1-year angiographic and 5-year clinical outcomes were compared between patients.

Results

Of 1,923 patients in the angiographic cohort of PREVENT-IV, 117 received a radial artery graft. These patients had longer surgical procedures (median 253 vs 228 minutes, P < .001) and had a greater number of grafts placed (P < .0001). Radial artery grafts had a graft-level failure rate of 23.0%, which was similar to vein grafts (25.2%) and higher than left internal mammary artery grafts (8.3%). The hazard of the composite clinical outcome of death, myocardial infarction, or repeat revascularization was similar for both cohorts (adjusted hazard ratio 0.896, 95% CI 0.609-1.319, P = .58). Radial graft failure rates were higher when used to bypass moderately stenotic lesions (<75% stenosis, 37% failure) compared with severely stenotic lesions (≥75% stenosis, 15% failure).

Conclusions

Radial artery grafts had early failure rates comparable to saphenous vein and higher than left internal mammary artery grafts. Use of a radial graft was not associated with a different rate of death, myocardial infarction, or postoperative revascularization. Despite the significant potential for residual confounding associated with post hoc observational analyses of clinical trial data, these findings suggest that when clinical circumstances permit, the radial artery is an acceptable alternative to saphenous vein and should be used to bypass severely stenotic target vessels.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
 Funding: Funding for this study was provided by National Institutes of Health grant 5T32HL069749 and the Duke Clinical Research Institute.
 Disclosures: none.
 Meeting presentation: This paper was presented at the American Association for Thoracic Surgery Annual Meeting in April 2019.
 Hartzell V. Schaff, MD, served as guest editor for this article.


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 228

P. 91-97 - ottobre 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Outcomes of transcatheter aortic valve replacement for patients with severe aortic stenosis and concomitant aortic insufficiency: Insights from the TVT Registry
  • Bhaskar Bhardwaj, David J Cohen, Sreekanth Vemulapalli, Andrzej S Kosinski, Qun Xiang, Zhuokai Li, Keith B. Allen, Samir Kapadia, Kul Aggarwal, Paul Sorajja, Adnan K. Chhatriwalla
| Articolo seguente Articolo seguente
  • New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials
  • Eline H. Ploumen, Rosaly A. Buiten, Carine J.M. Doggen, Martin G. Stoel, K. Gert van Houwelingen, Carl E. Schotborgh, Gillian A.J. Jessurun, Ariel Roguin, Peter W. Danse, Edouard Benit, Adel Aminian, Gerard C.M. Linssen, Frits H.A.F. de Man, Marc Hartmann, Diedrik G. Buiten, Marlies M. Kok, Paolo Zocca, Clemens von Birgelen, on behalf of the TWENTE I-IV trial investigators

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.